Best Aplastic anemia hematologist-oncologists in Istanbul: TOP 17 doctors

• Dr. Zafer Gulbas specializes in Aplastic anemia treatment.
• Uses transplant, immunosuppressive therapy, and blood transfusions for Aplastic anemia.
• International experience in the USA, Canada, and Israel.
• Founder of the Bone Marrow Transplantation Center at Anadolu Medical Center.
• Holds medical oncology and hematology expertise from prestigious institutions.
• Engages in online consultations for Aplastic anemia patients.
• Fluent in English and Turkish, accommodating a wider patient base.

Education:

2015

Dokuz Eylül University, Medical Faculty, Internal Medicine and Hematology 

2010

Dokuz Eylül University, Medical Faculty, Internal Medicine 

2005

Hacettepe University, Medical Faculty,

Experience:

2024 – 

Istanbul Florence Nightingale Hospital

2017 – 2024

Bağcılar Medipol University Hospital

2017 – 2017

Fırat University

2015 - 2017

Fırat University

2014 - 2015

Mayo Clinic

Publications:

18 Articles Published in International Peer-Reviewed Journals

26 Abstracts and Books Presented at International Scientific Conferences

7 Articles Published in National Peer-Reviewed Journals

51 Abstracts Presented at National Scientific Conferences

Education and Expertise

Ankara University Faculty of Medicine - Medical Education

Gazi University Faculty of Medicine Department of Internal Medicine - Internal Medicine - Specialization

Gazi University Faculty of Medicine Department of Hematology - Hematology - Subspecialty

Duke University Bone Marrow Transplantation Center - Cell Transplantation Training

Fred Hutchinson Cancer Research Center Seattle - Cell Transplant Training

Experience

Duke University-Durham North Carolina program 2001, cord blood transplant

Fred Hutchinson Cancer Research Center Bone Marrow Transplantation program Seattle 2002, unrelated stem cell transplant

Founder and manager of Gazi University Faculty of Medicine Adult Cell Transplant Unit 2003-2014

Gazi University Faculty of Medicine, Head of Hematology Department 2008-2014

Gazi University Faculty of Health Sciences Dean (founder) 2008-2012

Professional Memberships

Turkish Hematology Association





Bilimsel Yayınları

1.    Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, Craddock C, Finke J, Richard C, Passweg J, Peniket A, Maertens J, Sucak G, Gedde-Dahl T, Vitek A, Nagler A, Blaise D, Beelen D, Maillard N, Schwerdtfeger R, de Witte T, Kroger N. haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the E.
    Bone Marrow Transplant. 2017 Jul;52(7):1081. doi: 10.1038/bmt.2017.86
2.    Deger SM, Erten Y, Suyani E, Aki SZ, Ulusal Okyay G, Pasaoglu OT, Pasaoglu H, Arinsoy T, Turkoz Sucak G. Early Diagnostic Markers for Detection of Acute Kidney Injury in Hematopoietic Cell Transplant Recipients. Exp Clin Transplant. 2017 Apr 14. doi: 10.6002/ect.2016.0161. [Epub ahead of print]
3.    Sezer O, Beksac M, Hajek R, Sucak G, Cagirgan S, Linkesch W, Meltem Akay O, Gülbas Z, Nahi H, Plesner T, Snowden JA, Timurağaoğlu A, Dechow T, Lang A, Tuğlular T, Drach J, Armbrecht G, Potamianou A, Couturier C, Olie RA, Feys C, Allietta N, Terpos E. Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study. Br J Haematol. 2017 Jul;178(1):61-71. doi: 10.1111/bjh.14637. Epub 2017 Apr 6
4.    Özkurt ZN, Sucak GT, Akı ŞZ, Yağcı M, Haznedar R.Early Prognostic Value of Monitoring Serum Free Light Chain in Patients with Multiple Myeloma Undergoing Cell Transplantation. Cancer Invest. 2017 Mar 16;35(3):195-201. 
5.    Aslan D, Türköz-Sucak G, Percy MJ. Recessive congenital methemoglobinemia in immediate generations.Turk J Pediatr. 2016;58(1):113-115
6.    Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, Craddock C, Finke J, Richard C, Passweg J, Peniket A, Maertens J, Sucak G, Gedde-Dahl T, Vitek A, Nagler A, Blaise D, Beelen D, Maillard N, Schwerdtfeger R, de Witte T, Kroger N. haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the E. Bone Marrow Transplant. 2017 Feb;52(2):209-215. Erratum in: Bone Marrow Transplant. 2017 Jul;52(7):1081.
7.    Pamukcuoglu M, Acar K, Celik B, Akyurek N, Pepeler MS, Sucak GT. Peripheral and CD34+ cell levels on chronic myeloproliferative disease. Hematology. 2017 Mar;22(2):74-80. 
8.    van Gorkom G, Finel H, Giebel S, Pohlreich D, Shimoni A, Ringhoffer M, Sucak G, Schaap N, Dreger P, Sureda A, Schouten HC. Prospective noninterventional study on peripheral blood stem cell mobilization in patients with relapsed lymphomas. J Clin Apher. 2016 Sep 10. doi: 10.1002/jca.21506. [Epub ahead of print]
9.    Necchi A, Miceli R, Bregni M, Bokemeyer C, Berger LA, Oechsle K, Schumacher K, Kanfer E, Bourhis JH, Massard C, Laszlo D, Montoro J, Flechon A, Arpaci F, Secondino S, Wuchter P, Dreger P, Crysandt M, Worel N, Kruger W, Ringhoffer M, Unal A, Nagler A, Campos A, Wahlin A, Michieli M, Sucak G, Donnini I, Schots R, Ifrah N, Badoglio M, Martino M, Raggi D, Giannatempo P, Rosti G, Pedrazzoli P, Lanza F. Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party. Bone Marrow Transplant. 2016 Mar;51(3):384-90. 
10.    Cahu X, Labopin M, Giebel S, Aljurf M, Kyrcz-Krzemien S, Socié G, Eder M, Bonifazi F, Bunjes D, Vigouroux S, Michallet M, Stelljes M, Zuckerman T, Finke J, Passweg J, Yakoub-Agha I, Niederwieser D, Sucak G, Sengeløv H, Polge E, Nagler A, Esteve J, Mohty M; Acute Leukemia Working Party of E. Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of E. Bone Marrow Transplant. 2016 Mar;51(3):351-7. 
11.    Marchand T, Lamy T, Finel H, Arcese W, Choquet S, Finke J, Huynh A, Irrera G, Karakasis D, Konopacki J, Lambert J, Michieli M, Schouten HC, Schroyens W, Sucak G, Tischer J, Vandenberghe E, Dreger P. Hematopoietic stem cell transplantation for T-cell large granular lymphocyte leukemia: a retrospective study of the European Society for Blood and Marrow Transplantation. Leukemia. 2016 May;30(5):1201-4
12.    Köktürk N, Yıldırım F, Aydoğdu M, Akı ŞZ, Yeğin ZA, Özkurt ZN, Suyanı E, Kıvılcım Oğuzülgen İ, Türköz Sucak G. Is It Possible to Predict Pulmonary Complications and Mortality in Hematopoietic Cell Transplantation Recipients from Pre-Transplantation Exhaled Nitric Oxide Levels? Turk J Haematol. 2016 Mar 5;33(1):34-40. 
13.    Barğı G, Güçlü MB, Arıbaş Z, Akı ŞZ, Sucak GT. Inspiratory muscle training in allogeneic hematopoietic stem cell transplantation recipients: a randomized controlled trial. Support Care Cancer. 2016 Feb;24(2):647-659
14.    Camcıoğlu B, Boşnak-Güçlü M, Karadallı MN, Akı ŞZ, Türköz-Sucak G. The Role of Inspiratory Muscle Training in Sickle Cell Anemia Related Pulmonary Damage due to Recurrent Acute Chest Syndrome Attacks.Case Rep Hematol. 2015;2015:780159. doi: 10.1155/2015/780159. Epub 2015  Apr 28.
15.     Fox CP, Boumendil A, Schmitz N, Finel H, Luan JJ, Sucak G, Blaise D, Finke J, Pflüger KH, Veelken H, Gorin NC, Poiré X, Ganser A, Dreger P, Sureda A. High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in Western patients; a study from the European Society for Blood and Marrow Transplantation. Leuk Lymphoma. 2015 Apr 22:1-20. 
16.    Akı ŞZ, Suyanı E, Cengiz M, Özenirler S, Elbeğ Ş, Paşaoğlu H, Sucak GT. Association between Plasma Endothelin-1, Transforming Growth Factor-β, Fibroblast Growth Factor, and Nitric Oxide Levels and Liver Injury in Hematopoietic Cell Transplantation Recipients with Persistent Iron Overload after Transplantation. Biol Blood Marrow Transplant. 2015 May;21(5):948-953.
17.    Beksaç M, Waage A, Bringhen S, Kristinsson SY, Sucak G, Gimsing P, Giulia L, Tuglular TF, Juliusson G, Turesson I, Palumbo A. Does Low Molecular Weight Heparin Influence The Anti-Myeloma Effects Of Thalidomide? A Retrospective Analysis On Data From The GIMEMA, Nordic and Turkish Myeloma Study Groups Acta Haematologica 2015 Mar 24;133(4):372-380
18.    Pepeler MS, Acar K, Güzel Tunçcan Ö, Uluoğlu Ö, Kalkancı A, Atalar H, Kılıç K, Türköz Sucak G. A proven case of cutaneous rhizopus infection presenting with severe limb pain very soon after induction treatment in a patient with acute lymphoblastic leukemia. Case Rep Hematol. 2015;2015:285360. doi: 10.1155/2015/285360. Epub 2015 Feb 15.
19.    Yegin ZA, Iyidir OT, Demirtaş C, Suyanı E, Yetkin I, Paşaoğlu H, Ilhan C, Sucak GT. The interplay among iron metabolism, endothelium and inflammatory cascade in dysmetabolic disorders. J Endocrinol Invest. 2014 Sep 23. [Epub ahead of print]
20.    Tanase A, Schmitz N, Stein H, Boumendil A, Finel H, Castagna L, Blaise D, Milpied N, Sucak G, Sureda A, Thomson K, Vandenberghe E, Vitek A, Dreger P. and Cell Transplantation for hepatosplenic T cell lymphoma: A retrospective study of the E Lymphoma Working party. Leukemia. 2014 Sep 19. doi: 10.1038/leu.2014.280. [Epub ahead of print]
21.    Salihoglu A, Elverdi T, Karadogan I, Paydas S, Ozdemir E, Erdem G, Karadurmus N, Akyol G, Kaynar L, Yegin Z, Sucak G, Ozkocaman V, Topcuoglu P, Ozcan M, Birtas E, Göker H, Başlar Z, Ferhanoglu B. Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey. Ann Hematol. 2014 Sep 18. [Epub ahead of print]
22.    Aygencel G, Türkoğlu M, Türköz Sucak G, Benekli M. Prognostic factors in critically ill cancer patients admitted to the intensive care unit. J Crit Care. 2014 Aug;29(4):618-26.
23.    Pamukçuoğlu M, Emmez H, Tunçcan OG, Oner AY, Cırak MY, Senol E, Sucak GT. Brain abscess caused by Nocardia cyriacigeorgica in two patients with multiple myeloma: novel agents, new spectrum of infections. Hematology. 2014 Apr;19(3):158-62. 
24.    Kadir Acar, Şahika Zeynep Akı, Zübeyde Nur Özkurt, Gülendam Bozdayı, Seyyal Rota, Gülsan Türköz Sucak Factors Associated with Cytomegalovirus Reactivation Following Hematopoietic Cell Transplantation: Human Leukocyte Antigens Might Be Among the Risk Factors Turk J Haematol. 2014 Sep 5;31(3):276-285
25.    Abdülkerim Yıldız, Merih Kızıl Çakar, Elif Suyanı, Gülsan Türköz Sucak A Systemic Lupus Erythematosus Patient with Isolated Neutropenia and Diminished Expression of CD55 and CD59 Similar to Paroxysmal Nocturnal Hemoglobinuria doi: 10.4274/Tjh.2013.0318   Pages 323 – 324
26.    Suyanı E, Sucak GT, Akyürek N, Sahin S, Baysal NA, Yağcı M, Haznedar R. Tumor-associated macrophages as a prognostic parameter in multiple myeloma. Ann Hematol. 2013 May;92(5):669-77
27.    Akyol A, Nazlıel B, Batur Caglayan HZ, Oner Y, Sucak GT. Recurrent Transient Ischemic Attacks in a Patient with POEMS Syndrome. Case Rep Neurol Med 2014:158471
28.    Boyacı N, Aygencel G, Turkoglu M, Yegin ZA, Acar K, Sucak GT. The intensive care management process in patients with hematopoietic stem cell transplantation and factors affecting their prognosis. Hematology. 2014 Sep;19(6):338-45
29.    Merve Pamukcuoğlu, Kadir Acar, Nalan Akyürek, Gülsan Türköz Sucak. Non-Leukemic Granulocytic Sarcoma Presenting with Multiple Skin Nodules and a Retroperitoneal Mass. Turk J Hematol 2013;30:81-82
30.    Merve Pamukçuoğlu, Kadir Acar, Nalan Akyürek, Gülsan Türköz Sucak A Rare Case of Acute Leukemia Relapsing with a Granulocytic Sarcoma Causing Ectopic Pregnancy Indian Journal of Hematology and Blood Transfusion April 2013
31.    Keser I, Suyani E, Aki SZ,  Sucak AG. The positive impact of regular exercise program on stem cell mobilization prior to autologous stem cell transplantation. Transfus Apher Sci. 2013 Jul 6. doi:pii: S1473-0502(13)00205-X. 10.1016/j.transci.2013.06.007. [Epub ahead of print]
32.    Buyukasik Y, Acar K, Kelkitli E, Uz B, Serefhanoglu S, Ozdemir E, Pamukcuoglu M, Atay H, Bektas O, Sucak GT, Turgut M, Aksu S, Yagci M, Sayınalp N, Ozcebe OI, Goker H, Haznedaroglu IC.  Hyper-CVAD Regimen in Routine Management of Adult Acute Lymphoblastic Leukemia: A Retrospective Multicenter Study. Acta Haematol 2013 Jun 19;130(3):199-205.
33.    Yaşar DG, Suyanı E, Özenirler S, Sucak GT. Adefovir is effective to promote development of immunity to donor origin hepatitis B virus in an allogeneic transplant recipient: a case report.Transplant Proc. 2013 Mar;45(2):833-4.
34.    Keser I, Suyani E, Yosmaoglu HB, Aki SZ, Sucak AG. Acute physiological responses to physiotherapy applications pre and post autologous stem cell transplantation: an experimental study. Hematology. 2014 Apr;19(3):136-40.
35.    Yağcı M, Yegin ZA, Akyürek N, Kayhan H, Ozkurt ZN, Sucak GT, Haznedar R. TCTP/HRF pathway and angiogenesis: a feasible intercourse in chronic lymphocytic leukemia. Leuk Res. 2013 Jun;37(6):665-70.
36.    Sucak GT, Cakar MK, Suyanı E, Akı Z, Altındal SE, Acar K. Outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin lymphoma patients in a centre from Turkey. Hematology. 2013 Sep;18(5):269-76.
37.    Türkoğlu M, Erdem GU, Suyanı E, Sancar ME, Yalçın MM, Aygencel G, Akı Z, Sucak G.Acute respiratory distress syndrome in patients with hematological malignancies. Hematology. 2013 May;18(3):123-130.
38.    Rovó A, Aljurf M, Chiodi S, Spinelli S, Salooja N, Sucak G, Hunter A, Kim TS, Socié G, van Lint MT, Passweg JR, Arat M, Badoglio M, Tichelli A. Paternity wishes in long-term survivors after allogeneic hematopoietic SCT. A study of the late effects working party of the E. Bone Marrow Transplant. 2013 Jun;48(6):878-9.
39.    Çakar MK, Suyani E, Sucak GT, Altindal Ş, Aki SZ, Acar K, Yağci M, Rota S, Özenirler S. HBV-related events after allogeneic hematopoetic stem cell transplantatıon in a center from Turkey. Ann Hematol. 2013 Mar;92(3):395-402.
40.    Akı ŞZ, Suyanı E, Bildacı Y, Çakar MK, Baysal NA, Sucak GT. Prognostic role of pre-transplantation serum C-reactive protein levels in patients with acute leukemia undergoing myeloablative allogeneic stem cell transplantation. Clin Transplant. 2012 Sep-Oct;26(5):E513-2.
41.    Akı SZ, Pamukçuoğlu M, Bağrıaçık Ü, Sucak GT. Encephalopathy: an unusual neurologic complication of autologous hematopoietic stem cell transplant in patients with multiple myeloma with renal failure.Leuk Lymphoma. 2013 Apr;54(4):894-6.
42.    Rovó A, Aljurf M, Chiodi S, Spinelli S, Salooja N, Sucak G, Hunter A, Kim TS, Socié G, van Lint MT, Passweg JR, Arat M, Badoglio M, Tichelli A; Late Effects Working Party of the E. Ongoing graft-versus-host disease is a risk factor for azoospermia after allogeneic hematopoietic stem cell transplantation: a survey of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2013 Mar;98(3):339-45.
43.    Palumbo A, Waage A, Hulin C, Beksac M, Zweegman S, Gay F, Gimsing P, Leleu X, Wijermans P, Sucak G, Pezzatti S, Juliusson G, Pégourié B, Schaafsma M, Galli M, Turesson I, Kolb B, van der Holt B, Baldi I, Rolke J, Ciccone G, Wetterwald M, Lokhorst H, Boccadoro M, Rodon P, Sonneveld PSafety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. Haematologica. 2013 Jan;98(1):87-94.
44.    Aydoğdu M, Ozyilmaz E, Köktürk N, Yeğin ZA, Özkurt ZN, Aki ZS, Sucak G. Is there any relationship between pulmonary function tests and post-transplant complications of allogeneic hematopoetic stem cell transplantation? Minerva Med. 2012 Jun;103(3):189-98.
45.    Suyanı E, Altındal Ş, Akı Ş, Sucak GT. Does fludarabine increase the incidence of sinusoidal obstruction syndrome when combined with Bu/Cy during conditioning? Clin Transplant. 2012 Mar-Apr;26(2):E85-6.
46.    Sucak GT, Yaşar DG, Yegin ZA, Ergün MA, Ozkurt ZN, Aki ŞZ, Güntekin S. The prognostic role of hemochromatosis H63D allele in allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2012 Aug;91(8):1281-7.
47.    Suyanı E, Sucak GT, Erten Y, Cakar MK, Ulusal G, Yağcı M, Haznedar R. Evaluation of multiple myeloma patients presenting with renal failure in a university hospital in the year 2010. Ren Fail. 2012;34(2):257-62.
48.    Sucak GT, Suyanı E, Baysal NA, Altındal Ş, Çakar MK, Akı ŞZ, Yeğin ZA, Şanlıer N.The role of body mass index and other body composition parameters in early post-transplant complications in patients undergoing allogeneic stem cell transplantation with busulfan-cyclophosphamide conditioning. Int J Hematol. 2012 Jan;95(1):95-101.
49.    Bağrıaçık EU, Yaman M, Haznedar R, Sucak G, Delibasi T. TSH-induced gene expression involves regulation of self-renewal and differentiation-related genes in human -derived mesenchymal .J Endocrinol. 2012 Feb;212(2):169-78.
50.    Elif Suyanı, Zeynep Akı, Zeynep Arzu Yeğin, Gülsan Türköz Sucak. Bortezomib-Associated Severe Orthostatic Hypotension and Hyponatremia Turk J Hematol 2012; 29: 301-302.
51.    Zeynep Arzu Yegin, Gülsan Türköz Sucak, Gonca Erbaş, Münci Yağcı ARA-C associated pulmonary toxicity. Turk J Hematol 2011; 28: 81-3.
52.    Turkoglu M, Mirza E, Tunçcan OG, Erdem GU, Dizbay M, Yağcı M, Aygencel G, Türköz Sucak G. Acinetobacter baumannii infection in patients with hematologic malignancies in intensive care unit: risk factors and impact on mortality. J Crit Care. 2011 Oct; 26(5):460-7.
53.    Akı SZ, Paşaoğlu H, Yeğin ZA, Suyanı E, Demirtaş CY, Ozkurt ZN, Yağcı M, Sucak GT. Impact of prohepcidin levels and iron parameters on early post-transplantation toxicities.Hematology. 2011 Sep;16(5):284-90.
54.    Yenicesu I, Sucak G, Dilsiz G, Akı SZ, Yeğin ZA. Hematopoietic stem cell transplantation in a very high risk group of patients with the support of granulocyte transfusion. Indian J Hematol Blood Transfus. 2011 Sep;27(3):146-51.
55.    Tunçcan ÖG, Aki ŞZ, Akyürek N, Sucak G, Şenol E. Isolated cutaneous aspergillosis in an acute lymphoblastic leukemia patient after allogeneic stem cell transplantation.J Infect Dev Ctries. 2011 May 28;5(5):406-9.
56.    Rota S, Fidan K, Bozdayı G, Dalgıç A, Fidan I, Sucak G, Müderris T. [Investigation of BK and JC virus DNA positivities by real-time polymerase chain reaction in the clinical samples of patients with high risk].Mikrobiyol Bul. 2011 Apr;45(2):280-7.
57.    Suyanı E, Yağcı M, Sucak GT. Complete remission with a combination of lenalidomide, cyclophosphamide and prednisolone in a patient with incomplete POEMS syndrome. Acta Haematol. 2011;126(4):199-201.
58.    Sucak GT, Özkurt ZN, Suyanı E, Yaşar DG, Akdemir ÖÜ, Akı Z, Yeğin ZA, Yağcı M, Kapucu ÖL. Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival. Ann Hematol. 2011 Nov;90(11):1329-36.
59.    Ljungman P,  de la Camara R, Perez-Bercoff L, Abecasis M, Nieto Campuzano JB, Cannata-Ortiz MJ, Cordonnier C, Einsele H, Gonzalez-Vicent M, Espigado I, Halter J, Martino R, Mohty B, Sucak G, Ullmann AJ, Vázquez L, Ward KN, Engelhard D; Infectious Diseases Working Party, European Group for Blood and Marrow Transplantation; Infectious Complications Subcommittee, Spanish Group of Haematopoietic -cell Transplantation. Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients. Haematologica. 2011 Aug;96(8):1231-5.
60.    Sucak GT, Aki SZ, Yüzbaşioğlu B, Akyürek N, Yağci M, Bağriaçik U, Haznedar R. Prognostic value of microvessel density and angiogenic cytokines in patients with multiple myeloma undergoing autologous stem cell transplant. Leuk Lymphoma. 2011 Jul;52(7):1281-9.
61.    Yegin ZA, Paşaoğlu H, Aki SZ, Özkurt ZN, Demirtaş C, Yağci M, Acar K, Sucak GT. Pro-oxidative/antioxidative imbalance: a key indicator of adverse outcome in hematopoietic stem cell transplantation.Int J Lab Hematol. 2011 Aug;33(4):414-23.
62.    Haznedar R, Akı ŞZ, Akdemir ÖÜ, Özkurt ZN, Çeneli O, Yağcı M, Sucak GT, Unlü M. Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging. 2011 Jun;38(6):1046-53.
63.    Suyani E, Aki Z, Güzel Ö, Altindal S, Senol E, Sucak G.H1N1 infection in a cohort of hematopoietic stem cell transplant recipients: prompt antiviral therapy might be life saving.Transpl Infect Dis. 2011 Apr;13(2):208-12.
64.    Sucak A, Acar K, Celen S, Danisman N, Sucak GT. Outcome of pregnancies in women with thrombophilic disorders.J Obstet Gynaecol. 2010;30(8):847-51.
65.    Suyanı E, Sucak GT, Akı ŞZ, Yeğin ZA, Özkurt ZN, Yağcı M. Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT. Ann Hematol. 2011 Jun;90(6):685-91.
66.    Beksaç M, Haznedar R, Firatli-Tuğlular T, Özdogu H, AydoĞdu I, Konuk N, Sucak G, Kaygusuz I, Karakus S, Kaya E, Ali R, Gulbas Z, Ozet G, Goker H, Undar L. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol. 2011 Jan;86(1):16-22.
67.    Sucak G, Suyanı E, Özkurt ZN, Yeğin ZA, Aki Z, Yagci M. Abnormal protein bands in patients with multiple myeloma after haematopoietic stem cell transplantation: does it have a prognostic significance? Hematol Oncol. 2010 Dec;28(4):180-4.
68.    Ozyilmaz E, Aydoğdu M, Sucak G, Akı ŞZ, Özkurt ZN, Yeğin ZA, Köktürk N. Risk factors for fungal pulmonary infections in hematopoietic stem cell transplantation recipients: the role of iron overload. Bone Marrow Transplant. 2010 Oct;45(10):1528-33.
69.    Tunçcan OG, Yegin ZA, Ozkurt ZN, Erbaş G, Akı SZ, Senol E, Yağcı M, Sucak G. High ferritin levels are associated with hepatosplenic candidiasis in hematopoietic stem cell transplant candidates.Int J Infect Dis. 2010 Sep;14 Suppl 3:e 104-7.

Adult Hematology

Fields of Study and Interests

• cell transplantation ( transplantation:

autologous/allogeneic)

• Acute leukemias (AML-ALL)

• Chronic leukemias

• Lymphomas (Hodgkin and non-Hodgkin lymphomas)

• Multiple myeloma

• Bone m deficiencies (Myelodysplastic syndrome - aplastic anemia etc.)

• Chronic myeloproliferative diseases (polycythemia vera - essential thrombocytosis - primary

myelofibrosis)

• Anemias / Polycythemias (anemia - excess blood)

• Outpatient and inpatient chemotherapies - immunotherapies - targeted therapies

Education

• Faculty of Medicine – Cerrahpaşa Faculty of Medicine 1999-2005

• Internal Medicine Specialist Training – İstanbul Haseki Training and Research Hospital

20062010

• Hematology Subspecialist Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research

Hospital – Hematology and Cell Transplantation Clinic 2013-2017

• Associate Professor İstanbul Ümraniye Training and Research Hospital 2019

Career

• Assistant Doctor Istanbul Haseki Training and Research Hospital-Internal Medicine Clinic

20062010

• Internal Medicine Specialist Istanbul Esenyurt State Hospital 2010-2012

• Internal Medicine Specialist-Military Service Samsun Military Hospital 2012-2013

• Minor Specialization Training Dr. Abdurrahman Yurtaslan Ankara Oncology Training and

Research Hospital – Hematology and Cell Transplantation Clinic 2013-2017

• Hematology Subspecialist Ankara Gülhane Training and Research Hospital, Hematology and

Cell Transplantation Clinic 2017-2018

• Hematology Subspecialist Istanbul Ümraniye Training and Research Hospital/Hematology

2018-2019

• Associate Professor Istanbul Ümraniye Training and Research Hospital/Hematology 2019-2021

• Associate Professor Maltepe University Faculty of Medicine / Hematology 2021-2024

• Associate Professor Istanbul VM Medical Park Pendik Hospital / Hematology and Cell

Transplantation Clinic 2022-2024

hematology and pediatric oncology

Fields of Study and Interests

• Nutritional anemias

• Acute lymphoblastic leukemia

• acute myeloid leukemia

• aplastic anemia

• Thalassemia (Mediterranean anemia)

• Hemophilia

• Pediatric Hematology Treatment Methods

• Chemotherapy

• Diseases and treatments covering all hematology and pediatric oncology

Education

• 1980 - 1986 Istanbul Faculty of Medicine

• Between 1989 and 1994, I.U. He specialized in Cerrahpaşa Faculty of Medicine, Department

of Child Health and Diseases.

• 2000 pediatric hematology and pediatric oncology specialization.

• Associate Professor of General Pediatrics in 2003,

• He became Professor in 2009.

• Head of the Science Department until 2012.

Career

• 2021 - OngoingDepartment Head / Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of

Medicine, Department of Internal Medical Sciences

• 2012 - OngoingCommission Member of the Rectorate / Istanbul University, Regulation and

Directive Commission, Regulation and Directive Commission

• 2007 - Ongoing Head of Department/Science / Istanbul University, Department of Child

Health and Diseases, Pediatric Hematology-Oncology

• 2002 - OngoingAcademic Board Member/ Istanbul University, Department of Child Health

and Diseases, Pediatric Hematology-Oncology

Publications: The molecular spectrum of Turkish osteopetrosis and related osteoclast disorders

Hematology

Fields of Study and Interests

• Approach to Anemia

• lymphomas

• Multiple Myeloma

• Myeloproliferative Diseases

• thrombocytopenia

• Bleeding Diathesis

• Approach to lymphadenopathy/ splenomegaly

• Acute Leukemias

• Chronic Leukemias

• Approach to Anemia

• lymphomas

• Multiple Myeloma

• Myeloproliferative Diseases

• thrombocytopenia

• Bleeding Diathesis

• Approach to lymphadenopathy/ splenomegaly

• Acute/ Chronic Leukemias

Education

• Undergraduate Istanbul Faculty of Medicine Istanbul University 2007

• Master's Degree Internal Medicine USA Marmara University Faculty of Medicine 2012

PhD Hematology Clinic Istanbul Training and Research Hospital 2018

• Associate Professor Hematology Clinic Prof.Dr.Cemil Taşçıoğlu Training and Research Hospital

2019

Career

• Assistant Dr. Istanbul University Cerrahpaşa Faculty of Medicine General Surgery / USA 2007-

2008

• Assistant Dr. Marmara University Faculty of Medicine Internal Medicine USA 2008-2012

• Expert Dr. Mardin Derik State Hospital 2013-2015

• Minor Assistant Dr. Istanbul Training and Research Hospital Hematology Clinic 2015-2018

• Expert Dr. Prof. Dr. Cemil Taşçıoğlu Training and Research Hospital Hematology Clinic 2018-2019

• Associate Professor Prof. Dr. Cemil Taşçıoğlu Training and Research Hospital Hematology Clinic

2019-2020

• Associate Professor Istanbul Başakşehir Çam and Sakura City Hospital Hematology Clinic 2020

• Associate Professor Bozyaka Training and Research Hospital Hematology Clinic 2020-2021

• Associate Professor Istinye University Faculty of Medicine, Department of Internal Medicine, Liv

Vadistanbul Hospital 2021-2023

Publications: Eren R, Doğu MH, Emir S, Huq GE, Okçu O, Altındal Ş, Yokuş O, Suyanı E.

Rethinking the usefulness of biopsy on treatment decision in CLL patients at

• Specializes in Aplastic anemia management with over 20 years of experience.
• Employs transplant, immunosuppressive therapy, and blood transfusions.
• International practice includes Turkey, NATO KFOR Command, Turkish Cypriot Peace Forces.
• Over 40 cancer research publications, contributing to Aplastic anemia knowledge.
• Accredited as a Medical Oncologist and Internal Medicine Specialist.
• Member of the Turkish Medical Oncology Association.
• Consults patients online, including those with Aplastic anemia.
• Speaks Turkish and English, aiding communication with diverse patients.

Medical Fields of Interest: 

Chronic Leukemia (Chronic Lymphocytes Leukemia/ Chronic Myeloid Leukemia) 

Chronic Myeloproliferative Diseases (Polistemia Vera, Essential Thrombocytosis, Myelofibrosis etc.) 

Lymphoma (Hodgkin’s and Non-Hodgkin’s) 

Multiple Myeloma 

Education: 

Ege University Faculty of Medicine Medical Doctor 1999 - 2005 

Pamukkale University Specialist in Internal Medicine 2006 - 2011 

Pamukkale University Hematologist 2011 - 2014 

ESCCA Summer School On Cytometry/PRAGUE (May 2014) 

Istanbul Training and Research Hospital Hematology Clinic Associate Professor 2018 

Experience: 

Selçuk University Faculty of Medicine Hospital 2015 

Pamukkale University Internal Medicine Residency Training 2016-2011 

Denizli Sarayköy State Hospital 2011-2011 

Pamukkale University Hematology Minor Residency Training 2011-2014 

Istanbul Training and Research Hospital Hematology Clinic Specialist Doctor 2015-2020 

Istanbul Training and Research Hospital Hematology Clinic Responsible Authority 2015-2020 

Istanbul Training and Research Hospital Hematology Clinic Responsible Authority/ Lecturer 2019-2020 

Istanbul Başakşehir Çam and Şakura City Hospital Hematology Clinic Lecturer 2020-2020

Liv Hospital Ulus 2020-

Memberships: 

Turkish Society of Hematology 

The Society of Hematological Education and Research (Member of The Board of Directors

Prof. Dr. Serdar Bedii Omay graduated from Hacettepe Medical School in 1985 and later specialized in Internal Medicine and Hematology. He has published 65 scientific articles, 112 meeting papers, and 34 conference presentations in the field of Hematology and Bone Marrow Transplantation. He has also worked as a Hematology Specialist and Molecular Hematology Doctor at Japan Mie Medical Faculty in 1995.

Prof. Baytan is a doctor who graduated from Ankara University Medical Faculty in 1992 and became a Specialist in Medicine at Uludağ University Faculty of Medicine, Department of Child Diseases. He is experienced in the diagnosis and treatment of childhood cancers, leukemia, anemia, and other diseases. He has 15 articles published in international refereed journals, 9 full texts presented and published in international scientific meetings, 3 books/book chapters written, and 8 articles published in local refereed journals.